NASDAQ: ICCC - ImmuCell Corporation

Yield per half year: +48.69%
Dividend yield: 0.00%
Sector: Healthcare

Share chart ImmuCell Corporation

Extended chart Simple chart
Financial Markets by TradingView

About ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.

more details
The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1987-04-30
ISIN US4525253062
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://immucell.com
Цена ао 4.78
Change price per day: -2% (5.5)
Change price per week: +9.22% (4.935)
Change price per month: +8.45% (4.97)
Change price per 3 month: +1.89% (5.29)
Change price per half year: +48.69% (3.625)
Change price per year: +6.73% (5.05)
Change price per 3 year: -38.68% (8.79)
Change price per 5 year: +18.98% (4.53)
Change price per year to date: +22.22% (4.41)
All parameters

Underestimation

Title Value Grade
P/S 2.08 7
P/BV 1.45 9
P/E 0 0
EV/EBITDA -17.15 0
Total: 5.5

Efficiency

Title Value Grade
ROA, % -13.18 0
ROE, % -23.1 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -5.51 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 27.53 4
Yield Ebitda, % 162.48 10
Yield EPS, % 292.07 10
Total: 8.8
More

Institutions Volume Share, %
Vanguard Group Inc 206606 2.67
Renaissance Technologies, LLC 126189 1.63
Cresset Asset Management, LLC 103606 1.34
Bleichroeder LP 101594 1.31
Morgan Stanley 84574 1.09
Shufro, Rose & Co., LLC 62408 0.81
Dimensional Fund Advisors LP 57451 0.74
Geode Capital Management, LLC 53213 0.69
Susquehanna International Group, LLP 33720 0.44
Overbrook Management Corp 32857 0.42



Head Job title Payment Year of birth
Mr. Michael F. Brigham President, CEO, Principal Financial Officer, Treasurer, Secretary & Director 395.24k 1961 (64 years)
Ms. Bobbi Jo Brockmann VP of Sales & Marketing and Director 323.52k 1977 (48 years)
Mr. A. Gustavo Scaffa Senior Director of Quality N/A
John W. Zinckgraf Director of Product Development N/A
Ms. Elizabeth L. Williams Vice President of Manufacturing Operations 312.07k 1956 (69 years)
Ms. Elizabeth S. Toothaker Director of Finance & Administration and Controller N/A

Address: United States, Portland. ME, 56 Evergreen Drive - open in Google maps, open in Yandex maps
Website: https://immucell.com